{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:53:52Z","timestamp":1771268032904,"version":"3.50.1"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["186"],"award-info":[{"award-number":["186"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The humoral response through neutralizing antibodies (NAbs) is a key component of the immune response to COVID-19. However, the plaque reduction neutralization test (PRNT), the gold standard for determining NAbs, is technically demanding, time-consuming and requires BSL-3 conditions. Correlating the NAbs and total antibodies levels, assessed by generalized and automated serological tests, is crucial. Through a commercial surrogate virus neutralization test (sVNT), we aimed to evaluate the production of SARS-CoV-2 NAbs in a set of vaccinated healthcare workers and to correlate these NAbs with the SARS-CoV-2 IgG anti-S1, anti-RBD and anti-S2 serological titers. We found that 6 months after vaccination, only 74% maintain NAbs for the Wuhan strain\/UK variant (V1) and 47% maintain NAbs for the South African and Brazil variants (V2). Through Spearman\u2019s correlation, we found the following correlations between the percentage of inhibition of NAbs and the SARS-CoV-2 IgG II Quant (Abbott Laboratories, Chicago, IL, USA) and BioPlex 2200 SARS-CoV-2 IgG Panel (Bio-Rad, Hercules, CA, USA) immunoassays: rho = 0.87 (V1) and rho = 0.73 (V2) for anti-S1 assessed by Abbott assay; rho = 0.77 (V1) and rho = 0.72 (V2) for anti-S1, rho = 0.88 (V1) and rho = 0.82 (V2) for anti-RBD, and rho = 0.68 (V1) and rho = 0.60 (V2) for anti-S2 assessed by BioPlex assay (p &lt; 0.001 for all). In conclusion, we found a strong correlation between this fast, user-friendly, mobile and bio-safe sVNT and the serological immunoassays.<\/jats:p>","DOI":"10.3390\/diagnostics12010205","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T20:44:00Z","timestamp":1642365840000},"page":"205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers"],"prefix":"10.3390","volume":"12","author":[{"given":"Ang\u00e9lica","family":"Ramos","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"EPI Unit, Instituto de Sa\u00fade P\u00fablica, Universidade do Porto, 4200-135 Porto, Portugal"}]},{"given":"Maria Jo\u00e3o","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Lu\u00eds","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-6311","authenticated-orcid":false,"given":"Jo\u00e3o Tiago","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Patologia Cl\u00ednica, Centro Hospitalar e Universit\u00e1rio de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"EPI Unit, Instituto de Sa\u00fade P\u00fablica, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"Departamento de Biomedicina, Faculdade de Medicina, Universidade do Porto, 4200-135 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJMc2101951","article-title":"BNT162b2 mRNA COVID-19 Vaccine Effectiveness among Health Care Workers","volume":"384","author":"Benenson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-021-24285-4","article-title":"COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants","volume":"12","author":"Jalkanen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S1473-3099(21)00330-3","article-title":"Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: A test-negative, case-control study","volume":"21","author":"Hyams","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abc5343","article-title":"Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques","volume":"369","author":"Deng","year":"2020","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"Dispinseri","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"610688","DOI":"10.3389\/fimmu.2020.610688","article-title":"Humoral Responses and Serological Assays in SARS-CoV-2 Infections","volume":"11","author":"Galipeau","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S1473-3099(20)30634-4","article-title":"Performance characteristics of five immunoassays for SARS-CoV-2: A head-to-head benchmark comparison","volume":"20","author":"Ainsworth","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study","volume":"396","author":"Oteo","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114223","DOI":"10.1016\/j.jviromet.2021.114223","article-title":"Serological response to a single dose of a SARS-CoV-2 mRNA vaccine","volume":"296","author":"Ramos","year":"2021","journal-title":"J. Virol. Methods"},{"key":"ref_14","unstructured":"Payne, S. (2017). Viruses: From Understanding to Investigation, Academic Press."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41392-020-00310-8","article-title":"Convalescent plasma therapy for COVID-19: A tried-and-true old strategy?","volume":"5","author":"Xi","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jama.2020.16656","article-title":"COVID-19 and the Path to Immunity","volume":"324","author":"Stephens","year":"2020","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil","volume":"25","author":"Antonelli","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2008.08.074","article-title":"Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination","volume":"26","author":"Cohen","year":"2008","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2005.05.027","article-title":"Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera","volume":"130","author":"Eyal","year":"2005","journal-title":"J. Virol. Methods"},{"key":"ref_20","first-page":"100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Terpos, E., Karalis, V., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Gumeni, S., Malandrakis, P., Papanagnou, E.-D., Kastritis, E., Trougakos, I.P., and Dimopoulos, M.A. (2021). Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 11.","DOI":"10.3390\/life11101077"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/22221751.2021.1940305","article-title":"Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants","volume":"10","author":"Zani","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMc2106083","article-title":"BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants","volume":"385","author":"Liu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","unstructured":"Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock, T., Robertson, D.L., and Volz, E. (2020). Preliminary genomic characterisation of an emergent SARS- CoV-2 lineage in the UK defined by a novel set of spike mutations. Genom. Epidemiol., 1\u20135. Available online: https:\/\/virological.org\/t\/563."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"Faria","year":"2021","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.abj9932","article-title":"Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India","volume":"374","author":"Dhar","year":"2021","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2101147","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101147","article-title":"Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021","volume":"26","author":"Brandal","year":"2021","journal-title":"Eurosurveillance"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cele, S., Jackson, L., Khan, K., Khoury, D., Moyo-Gwete, T., Tegally, H., Scheepers, C., Amoako, D., Karim, F., and Bernstein, M. (2021). SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv.","DOI":"10.1101\/2021.12.08.21267417"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., and O\u2019Connell, A.M. (2021). Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv.","DOI":"10.1101\/2021.12.14.21267615"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"R\u00f6ssler, A., Riepler, L., Bante, D., von Laer, D., and Kimpel, J. (2021). SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv.","DOI":"10.1101\/2021.12.08.21267491"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/jalm\/jfaa195","article-title":"Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay","volume":"6","author":"Grenache","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10096-020-04128-8","article-title":"Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays","volume":"40","author":"Valdivia","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect Dis."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/1\/205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:15:06Z","timestamp":1760364906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/1\/205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["diagnostics12010205"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12010205","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}